The study included only patients previously treated with anthracyclines who had a disease-free interval of at least one year. The study found that patients treated with the Doxil
According to the company, Exparel provided safe and well-tolerated analgesia with normal wound healing in all patients. The study also showed significant reductions in pain with activity in
The company also waived the directors’ fees for 2008 and reduced the senior leaders’ base salaries between 15% and 35%. According to the company, all of these value-added
All the original Phytopharm patents and rights will revert to Phytopharm. In addition, Unilever has granted Phytopharm a non-exclusive, perpetual, irrevocable, worldwide, royalty-free license, with the right to
The Cobas AmpliPrep/Cobas TaqMan HIV-1 Test, v2.0 utilizes a unique design to simultaneously amplify and detect two separate regions of the HIV-1 genome, the company said. This approach
Budesonide MMX is an oral corticosteroid currently being investigated in two multi-center Phase III clinical trials involving more than 800 patients in North America and Europe for the
Under the terms of the collaborative agreement with GlaxoSmithKline (GSK), Synta is eligible for a total of $585 million in pre-commercial milestone payments. These milestones are related to
The first study, Revive (TA-301), is a randomized, double-blind, placebo-controlled, efficacy and safety study of avanafil in men with a history of erectile dysfunction (ED). Subjects will undergo
The DM-230 study met its primary endpoint of demonstrating glycemic control as measured by a reduction of hemoglobin A1c (HbA1c) of 1.6% from 8.8% to 7.2% for subjects
The Phase II study evaluated the safety and efficacy of a daily 240mg oral dose of neratinib in 136 women diagnosed with ErbB-2-positive locally advanced or metastatic breast
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.